- RNA focused drug developer Silence Therapeutics said it planned to list American depository shares on the Nasdaq.

The company also announced that it had appointed Iain Ross as its full-time executive chairman.

'This appointment follows an external search for a suitable CEO, which will continue until the optimal CEO for Silence is found,' it added.

Chief medical officer Giles Campion had been appointed as an executive director of the company.

At 9:42am: [LON:SLN] Silence Therapeutics PLC share price was +27.5p at 467.5p

Story provided by